- Home
- ACET vs PAVM Comparison
ACET vs PAVM Comparison
Compare ACET & PAVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | ACET | PAVM |
|---|---|---|
| Founded | 1947 | 2014 |
| Country | United States | United States |
| Employees | N/A | 41 |
| Industry | Biotechnology: Pharmaceutical Preparations | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 69.6M | 63.4M |
| IPO Year | 2017 | N/A |
Fundamental Metrics
Financial Performance| Metric | ACET | PAVM |
|---|---|---|
| Price | $6.48 | $10.00 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 1 |
| Target Price | $48.33 | ★ $510.00 |
| AVG Volume (30 Days) | ★ 97.3K | 10.9K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $603.94 |
| Revenue Next Year | N/A | $64.29 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.45 | $0.21 |
| 52 Week High | $9.05 | $28.44 |
Technical Indicators
Market Signals| Indicator | ACET | PAVM |
|---|---|---|
| Relative Strength Index (RSI) | 42.88 | 44.70 |
| Support Level | $6.01 | $8.47 |
| Resistance Level | $8.34 | $9.26 |
| Average True Range (ATR) | 0.34 | 0.59 |
| MACD | -0.01 | -0.05 |
| Stochastic Oscillator | 41.87 | 37.94 |
Price Performance
Historical ComparisonAbout ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.
About PAVM PAVmed Inc.
PAVmed Inc is a multi-product, commercial-stage medical technology company organized to advance a broad pipeline of medical technologies from concept to commercialization. The company operates in a single segment as a medical technology company, with the following lines of business: Diagnostics, Medical Devices, and Digital Health. Its products are EsoGuard, esocheck, and the Veris Cancer Care Platform.